Search
Check Out Our Sponsors
Latest topics
Hair Regrowth Following a Wnt- and Follistatin Containing Treatment: Safety and Efficacy in a First-in-Man Phase 1 Clinical Trial.
3 posters
Page 1 of 1
Hair Regrowth Following a Wnt- and Follistatin Containing Treatment: Safety and Efficacy in a First-in-Man Phase 1 Clinical Trial.
J Drugs Dermatol. 2011 Nov 1;10(11):1308-12.
Hair Regrowth Following a Wnt- and Follistatin Containing Treatment: Safety and Efficacy in a First-in-Man Phase 1 Clinical Trial.
Zimber MP, Ziering C, Zeigler F, Hubka M, Mansbridge JN, Baumgartner M, Hubka K, Kellar R, Perez-Meza D, Sadick N, Naughton GK.
Research has shown the importance of follistatin, Wnt 7a, and wound healing growth factors on the stimulation of bulge cells and inter-follicular stem cells to induce hair growth. We have studied the effects of a bioengineered, non-recombinant, human cell-derived formulation, termed Hair Stimulating Complex (HSC), containing these factors to assess its hair growth activity in male pattern baldness. HSC showed in vitro Wnt activity and contained follistatin, KGF, and VEGF. The clinical study was a double-blind, placebo-controlled, randomized single site trial and was designed to evaluate safety of the HSC product and assess efficacy in stimulating hair growth. All 26 subjects tolerated the single, intradermal injection of HSC procedures well, and no signs of an adverse reaction were reported. Histopathological evaluation of the treatment site biopsies taken at 22 and 52 weeks post-treatment revealed no abnormal morphology, hamartomas, or other pathological responses. Trichoscan image analysis of HSC-treated sites at 12 and 52 weeks showed significant improvements in hair growth over the placebo. At the initial 12-week evaluation period, HSC-treated sites demonstrated an increase in hair shaft thickness (6.3%±2.5% vs. -0.63%±2.1%; P=0.046), thickness density (12.8%±4.5% vs. -0.2%±2.9%; P=0.028), and terminal hair density (20.6±4.9% vs. 4.4±4.9%; P=0.029). At one year, a statistically significant increase in total hair count (P=0.032) continued to be seen. These results demonstrate that a single intradermal administration of HSC improved hair growth in subjects with androgenetic alopecia and is a clinical substantiation of previous preclinical research with Wnts, follistatin, and other growth factors associated with wound healing and regeneration. J Drugs Dermatol. 2011;10(11):1308-1312.
Hair Regrowth Following a Wnt- and Follistatin Containing Treatment: Safety and Efficacy in a First-in-Man Phase 1 Clinical Trial.
Zimber MP, Ziering C, Zeigler F, Hubka M, Mansbridge JN, Baumgartner M, Hubka K, Kellar R, Perez-Meza D, Sadick N, Naughton GK.
Research has shown the importance of follistatin, Wnt 7a, and wound healing growth factors on the stimulation of bulge cells and inter-follicular stem cells to induce hair growth. We have studied the effects of a bioengineered, non-recombinant, human cell-derived formulation, termed Hair Stimulating Complex (HSC), containing these factors to assess its hair growth activity in male pattern baldness. HSC showed in vitro Wnt activity and contained follistatin, KGF, and VEGF. The clinical study was a double-blind, placebo-controlled, randomized single site trial and was designed to evaluate safety of the HSC product and assess efficacy in stimulating hair growth. All 26 subjects tolerated the single, intradermal injection of HSC procedures well, and no signs of an adverse reaction were reported. Histopathological evaluation of the treatment site biopsies taken at 22 and 52 weeks post-treatment revealed no abnormal morphology, hamartomas, or other pathological responses. Trichoscan image analysis of HSC-treated sites at 12 and 52 weeks showed significant improvements in hair growth over the placebo. At the initial 12-week evaluation period, HSC-treated sites demonstrated an increase in hair shaft thickness (6.3%±2.5% vs. -0.63%±2.1%; P=0.046), thickness density (12.8%±4.5% vs. -0.2%±2.9%; P=0.028), and terminal hair density (20.6±4.9% vs. 4.4±4.9%; P=0.029). At one year, a statistically significant increase in total hair count (P=0.032) continued to be seen. These results demonstrate that a single intradermal administration of HSC improved hair growth in subjects with androgenetic alopecia and is a clinical substantiation of previous preclinical research with Wnts, follistatin, and other growth factors associated with wound healing and regeneration. J Drugs Dermatol. 2011;10(11):1308-1312.
_________________
My regimen
http://www.immortalhair.org/mpb-regimen
Now available for consultation (hair and/or health)
http://www.immortalhair.org/health-consultation
Re: Hair Regrowth Following a Wnt- and Follistatin Containing Treatment: Safety and Efficacy in a First-in-Man Phase 1 Clinical Trial.
thats great. thes r the studies im interested in . actual improvement from a once only injection, in human trials.
this is wat i hope a new treatment will consist of. once only injection. awesome.
much better than studies from some obscure molecule that fits somewhere in the pathway.
this is wat i hope a new treatment will consist of. once only injection. awesome.
much better than studies from some obscure molecule that fits somewhere in the pathway.
rofl- Posts : 857
Join date : 2009-11-21
Re: Hair Regrowth Following a Wnt- and Follistatin Containing Treatment: Safety and Efficacy in a First-in-Man Phase 1 Clinical Trial.
What phase is Histogen at? I thought they were supposed to be concluding phase II this year.
tonyj- Posts : 390
Join date : 2009-10-03
Similar topics
» Safety and Efficacy of Rice Bran Supercritical CO2 Extract for Hair Growth in Androgenic Alopecia: A 16-Week Double-Blind Randomized Controlled Trial.
» Safety and efficacy analysis of liposomal insulin-like growth factor-1 in a fluid gel formulation for hair-loss treatment in a hamster model
» Kintor GT20029 Receives IND Clearance by the FDA
» Welcome to a trial run of the new natural hair regrowth forum
» Effect of a sphingolipid-mimetic compound on the promotion of hair growth: A randomized, double-blind, placebo-controlled clinical trial
» Safety and efficacy analysis of liposomal insulin-like growth factor-1 in a fluid gel formulation for hair-loss treatment in a hamster model
» Kintor GT20029 Receives IND Clearance by the FDA
» Welcome to a trial run of the new natural hair regrowth forum
» Effect of a sphingolipid-mimetic compound on the promotion of hair growth: A randomized, double-blind, placebo-controlled clinical trial
Page 1 of 1
Permissions in this forum:
You cannot reply to topics in this forum
|
|
Yesterday at 8:05 am by CausticSymmetry
» zombie cells
Sat May 11, 2024 6:54 am by CausticSymmetry
» Sandalore - could it be a game changer?
Wed May 08, 2024 9:45 pm by MikeGore
» *The first scientific evidence in 2021 that viruses do not exist*
Tue May 07, 2024 4:18 am by CausticSymmetry
» China is at it again
Tue May 07, 2024 4:07 am by CausticSymmetry
» Ways to increase adult stem cells
Mon May 06, 2024 5:40 pm by el_llama
» pentadecanoic acid
Sun May 05, 2024 10:56 am by CausticSymmetry
» Exosome Theory and Herpes
Fri May 03, 2024 3:25 am by CausticSymmetry
» Road to recovery - my own log of everything I'm currently trying for HL
Tue Apr 30, 2024 1:55 pm by JtheDreamer